Entresto Tablet, Film Coated
Product Images NDC 71610-807

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Entresto (NDC 71610-807). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71610-807-37 (71610 807 37)

ENTRESTO film-coated tablets with 97 mg sacubitril and 103 mg valsartan strength. The label shows a container with 3,120 tablets, produced and packaged by Aphena Pharma Solutions - Tennessee, LLC, and distributed by MFK d.o.o. in Ljubljana, Slovenia. It includes storage instructions and unique identifiers such as NDC 71610-807-37.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Valsartan Structural Formula (Entresto 01)

Chemical structure of Sacubitril and Valsartan, the active ingredients in ENTRESTO tablets, showing their detailed molecular arrangement with sodium and water of hydration.*

FDA Label Image

Figure 1: Effect Of Entresto On Pharmacokinetics Of Coadministered Drugs (Entresto 02)

A scatter plot titled 'Coadministered Drugs' showing geometric mean ratio and 90% confidence intervals for various drugs relative to a reference. The x-axis represents change relative to reference, ranging approximately from 0.5 to 2. Each drug is listed on the y-axis with data points for AUC (solid circles) and Cmax (open circles). Drugs include Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil.*

FDA Label Image

Figure 2: Pharmacokinetics Of Entresto In Specific Populations (Entresto 03)

A forest plot chart comparing geometric mean ratios and 90% confidence intervals for AUC and Cmax of LBQ657 and Valsartan across various population descriptions, including renal impairment levels, hepatic impairment, age groups, gender, and ethnicity. The plot shows changes relative to reference values for each subgroup.*

FDA Label Image

Figure 3: Kaplan-meier Curves For The Primary Composite Endpoint (a), Cardiovascular Death (b), And Heart Failure Hospitalization (c) (Entresto 04)

Three Kaplan-Meier curve graphs comparing ENTRESTO (Sacubitril and Valsartan) to Enalapril in heart failure clinical outcomes. Figure A shows time to first occurrence of cardiovascular death or heart failure hospitalizations, Figure B shows time to occurrence of cardiovascular death, and Figure C shows time to first occurrence of heart failure hospitalizations. Each graph includes hazard ratios and confidence intervals with corresponding risk numbers over time (days since randomization).*

FDA Label Image

Figure 4: Primary Composite Endpoint (cv Death Or Hf Hospitalization) (Subgroup Analysis)

A forest plot chart showing hazard ratio comparisons with 95% confidence intervals between ENTRESTO and Enalapril across various subgroups including age, gender, weight, race, region, NYHA class, estimated GFR, diabetes status, systolic blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, hospitalization history, time since heart failure diagnosis, cause of heart failure, and ICD presence. The chart visually represents subgroup analyses in a clinical study context.*

FDA Label Image

Figure 5: Mean Number Of Events Over Time For The Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death (Entresto 09)

A line graph titled 'Total Heart Failure Hospitalizations and CV Death in PARAGON-HF' comparing mean number of events per 100 patients over time (days) since randomization between ENTRESTO and Valsartan. The graph shows two lines, with ENTRESTO (black line) having fewer events than Valsartan (gray line) throughout the 1440-day period. Below the x-axis are patient counts at risk for both treatments at multiple time points.*

FDA Label Image

Figure 6: Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death – Subgroup Analysis (paragon-hf) (Entresto 10)

A forest plot comparing subgroup analyses for ENTRESTO versus Valsartan. It displays rate ratios with 95% confidence intervals across various subgroups including age, gender, race, region, diabetic status, left ventricular ejection fraction (LVEF), atrial fibrillation baseline status, NT-proBNP screening levels, systolic blood pressure, use of mineralocorticoid receptor antagonist (MRA), ACE inhibitor intolerance, baseline estimated glomerular filtration rate (eGFR), and NYHA class. The plot visually indicates where ENTRESTO or Valsartan is favored across these groups.*

FDA Label Image

Figure 7: Treatment Effect For The Composite Endpoint Of Time To First Hf Hospitalization Or Cv Death By Lvef In Paradigm-hf And Paragon-hf (Entresto 11)

A dual-panel chart comparing ENTRESTO versus enalapril and ENTRESTO versus valsartan. It plots hazard ratio on the vertical axis against left ventricular ejection fraction at screening percentage on the horizontal axis. Solid lines represent hazard ratios, and dashed lines indicate 95% confidence intervals for two studies: PARADIGM-HF (left panel) and PARAGON-HF (right panel).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.